Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H23ClN4O2.C4H4O4 |
Molecular Weight | 442.894 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CCN1CC(CN1CC)NC(=O)C2=C(OC)C=C(N)C(Cl)=C2
InChI
InChIKey=IGGKTAIAQUIFKQ-WLHGVMLRSA-N
InChI=1S/C15H23ClN4O2.C4H4O4/c1-4-19-8-10(9-20(19)5-2)18-15(21)11-6-12(16)13(17)7-14(11)22-3;5-3(6)1-2-4(7)8/h6-7,10H,4-5,8-9,17H2,1-3H3,(H,18,21);1-2H,(H,5,6)(H,7,8)/b;2-1+
Molecular Formula | C15H23ClN4O2 |
Molecular Weight | 326.822 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Dazopride is an antagonist of the 5-HT3 receptor and agonist of the 5-HT4 receptor, structurally related to metoclopramide. Dazopride was developed by A. H. Robins Company as an antiemetic and gastroprokinetic drug. Dazoptide demonstrated an antiemetic effect in the clinic after i.v. infusion to patients, receiving anticancer therapy.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8453682
i.v. infusions every 2 h beginning 30 min before the chemotherapy at doses 0.5 to 4.0 mg/kg.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:26:52 GMT 2023
by
admin
on
Fri Dec 15 15:26:52 GMT 2023
|
Record UNII |
J8ZC30U6CH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C047339
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
PRIMARY | |||
|
81957-25-7
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
PRIMARY | |||
|
C74146
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
PRIMARY | |||
|
J8ZC30U6CH
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
PRIMARY | |||
|
11954360
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
PRIMARY | |||
|
T-114
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110810
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
PRIMARY | |||
|
DTXSID50231483
Created by
admin on Fri Dec 15 15:26:52 GMT 2023 , Edited by admin on Fri Dec 15 15:26:52 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |